Unicycive Therapeutics

UNCY · Nasdaq · United States

Share price · UNCY

$3.57-2.06 (-36.59%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.4M (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when UNCY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 26 Oct 2026-8.0%
  2. 2 Oct 2026-7.3%
  3. 1 Jul 2026+12.6%
  4. 30 Jun 2026-39.1%
  5. 26 Jun 2026-13.2%

    Nothing announced by UNCY that day or the session before.

  6. 22 Jun 2026+14.9%
  7. 10 Jun 2026+5.8%
  8. 9 Jun 2026+9.2%
  9. 26 May 2026-12.6%

    Nothing announced by UNCY that day or the session before.

  10. 22 May 2026+5.9%

    Nothing announced by UNCY that day or the session before.

Share of unusual movement by asset

For each asset, the share of UNCY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Oxylanthanum carbonate
events and moves
1013%
Other company news (earnings, financing, releases naming no asset)—34%
Sessions with no dated event—53%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Lanthanum-based intestinal phosphate binderSmall molecule
Chronic Kidney DiseaseHyperphosphatemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

25 March 2027FDA action dateOxylanthanum carbonatePDUFA date for the oxylanthanum carbonate NDA resubmission
US, FDA · Unicycive Therapeutics · Source ↗

Recent

21 October 2026Filing acceptedOxylanthanum carbonateFDA accepts the oxylanthanum carbonate NDA resubmission (Class 2)
US, FDA · Unicycive Therapeutics · Source ↗
29 September 2026Filing submittedOxylanthanum carbonateNDA resubmitted to the FDA
US, FDA · Unicycive Therapeutics, Inc. · Source ↗
30 June 2026Complete response letterOxylanthanum carbonateFDA issues CRL for resubmitted OLC NDA
US, FDA · Source ↗
29 June 2026FDA action dateOxylanthanum carbonatePDUFA target date set for OLC
US, FDA · Source ↗
June 2026Complete response letterOxylanthanum carbonateFDA complete response letter on the first NDA resubmission
US, FDA · Unicycive Therapeutics, Inc. · Source ↗
29 January 2026Filing acceptedOxylanthanum carbonateFDA accepts OLC NDA resubmission
US, FDA · Source ↗
June 2025Complete response letterOxylanthanum carbonateFDA complete response letter on the initial NDA
US, FDA · Unicycive Therapeutics, Inc. · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$2.8M$44M+ $17M short-term inv.$1.7M-$7.6M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$1.6M$37M+ $17M short-term inv.$13M-$6.2M operating cash flowreport ↗
2025-Q3—$3.0M$43M$6.0M-$6.0M operating cash flowreport ↗
2025-Q2—$1.8M$22M$6.5M-$8.4M operating cash flowreport ↗
2025-Q1—$2.2M$20M—-$8.9M operating cash flowreport ↗
2024-Q3—$3.0M$32M$4.1M-$9.3M operating cash flowreport ↗
2024-Q2—$4.9M$42M—-$6.3M operating cash flowreport ↗
2024-Q1—$6.8M$49M$21M-$6.5M operating cash flowreport ↗
2023-Q3—$3.4M$14M$4.3M-$4.4M operating cash flowreport ↗
2023-Q2—$2.3M$19M$3.8M-$5.5M operating cash flowreport ↗
2023-Q1$0.7M$3.0M$24M$15M-$3.9M operating cash flowreport ↗
2022-Q3$0.9M$4.8M$7.0M$5.6M-$3.6M operating cash flowreport ↗
2022-Q2—$1.9M$11M$3.6M-$3.0M operating cash flowreport ↗
2022-Q1—$1.9M$14M$3.5M-$3.0M operating cash flowreport ↗
2021-Q3—$3.8M$18M$5.2M-$3.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$9.1M$29M+ $12M short-term inv.$6.6M-$31M operating cash flowreport ↗

Unicycive Therapeutics reported no revenue for full-year 2025. R&D spend was $9.12M, down 54.4% YoY from $20.01M, while cash and equivalents were $29.2M at year-end and the company later reported $54.9M in cash, equivalents, and marketable securities as of March 30, 2026. Net loss attributable to common stockholders was $26.55M, or $1.67 per share, with quarterly net burn of $26.56M.

The FDA accepted the resubmitted New Drug Application for oxylanthanum carbonate (OLC) for hyperphosphatemia in dialysis patients, with a PDUFA target action date of June 29, 2026, and commercial readiness activities are ongoing toward a potential 3Q26 launch. The company expects its cash runway to extend into 2027, and it also highlighted its second candidate, UNI-494, for acute kidney injury-related conditions, which has completed a Phase 1 study and received orphan drug designation for prevention of delayed graft function.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$20M$26M$9.2M-$29M operating cash flowreport ↗
2023-FY$0.7M$13M$9.7M$7.6M-$18M operating cash flowreport ↗
2022-FY$0.9M$12M$0.5M$4.5M-$16M operating cash flowreport ↗
2021-FY—$6.1M$17M$2.5M-$5.8M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-28Manning Meredith · directorAward / grant (derivative)3,350——Form 4
2026-10-28Manning Meredith · directorAward / grant (derivative)27,000——Form 4
2026-05-14Laumas Sandeep · directorAward / grant (derivative)47,941——Form 4
2026-05-14Kenkare-Mitra Sara · directorAward / grant (derivative)47,941——Form 4
2026-05-14Jermasek Douglas · EVP, Corporate StrategyAward / grant (derivative)169,500——Form 4
2026-05-14Townsend John · CFOAward / grant (derivative)169,500——Form 4
2026-05-14Gupta Pramod · EVP, Pharmaceuticals and BDAward / grant (derivative)169,500——Form 4
2026-05-14Laumas Sandeep · directorAward / grant (derivative)84,200——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 51 reporting institutions held 9.9M shares ($64.8M, 35.6% of shares outstanding).

#InstitutionSharesValue
1Vivo Capital, LLC1,789,916$11.8M
2MILLENNIUM MANAGEMENT LLC1,399,348$9.2M
3Octagon Capital Advisors LP1,000,000$6.6M
4Nantahala Capital Management, LLC939,202$6.2M
5VANGUARD CAPITAL MANAGEMENT LLC811,430$5.3M
6GREAT POINT PARTNERS LLC796,558$5.2M
7Logos Global Management LP473,563$3.1M
8CITADEL ADVISORS LLC236,841$1.6M
9Integral Health Asset Management, LLC225,000$1.5M
10GEODE CAPITAL MANAGEMENT, LLC203,744$1.3M
11SUSQUEHANNA INTERNATIONAL GROUP, LLP199,219$1.3M
12MORGAN STANLEY188,182$1.2M
13MARSHALL WACE, LLP154,938$1.0M
14Dauntless Investment Group, LLC147,087$968K
15DIMENSIONAL FUND ADVISORS LP143,052$940K